Palmitoyl ascorbate liposomes and free ascorbic acid: Comparison of anticancer therapeutic effects upon parenteral administration

Pharmaceutical Research

Volumn 29, Issue 2, 2012, Pages 375-383

  Sawant, Rupa R ^a   Vaze, Onkar S ^a   Wang, Tao ^a   D'Souza, Gerard G M ^a,b   Rockwell, Karen ^a   Gada, Keyur ^a   Khaw, Ban An ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Ascorbic acid; Cancer; Liposomes; Palmitoyl ascorbate

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; ASCORBIC ACID DERIVATIVE; HYDROGEN PEROXIDE; LIPOSOME; MACROGOL; METAL CHELATE; PALMITOYL ASCORBATE; REACTIVE OXYGEN METABOLITE; TRANSITION ELEMENT; UNCLASSIFIED DRUG; 6-O-PALMITOYLASCORBIC ACID; ANTIOXIDANT; ASCORBIC ACID 6 PALMITATE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL DEATH; CHEMICAL MODIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BREAST; DRUG EFFECT; EXPERIMENTAL NEOPLASM; LIPOYLATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; BREAST; CELL LINE, TUMOR; FEMALE; LIPOSOMES; LIPOYLATION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C;

EID: 84860863921     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0557-8     Document Type: Article

References (34)

1. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008;105(32):11105-9.
2. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007;104(21):8749-54. (Pubitemid 47175383)
3. Belin S, Kaya F, Duisit G, Giacometti S, Ciccolini J, Fontes M. Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One. 2009;4(2):e4409.
4. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009;47(1):32-40.
5. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969-74.
6. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976;73(10):3685-9.
7. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1978;75(9):4538-42. (Pubitemid 9028392)
8. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007;22(1):7-11.
9. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9(2):E128-47.
10. Miwa N, Yamazaki H, Nagaoka Y, Kageyama K, Onoyama Y, Matsui-Yuasa I, et al. Altered production of the active oxygen species is involved in enhanced cytotoxic action of acylated derivatives of ascorbate to tumor cells. Biochim Biophys Acta. 1988;972(2):144-51. (Pubitemid 18264583)
11. D'Souza GG, Wang T, Rockwell K, Torchilin VP. Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro. Pharm Res. 2008;25(11):2567-72.
12. Sawant RR, Vaze OS, Rockwell K, Torchilin VP. Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur J Pharm Biopharm. 2010;75(3):321-6.
13. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999;59(18):4555-8. (Pubitemid 29428957)
14. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997;100(11):2842-8. (Pubitemid 28007554)
15. Rumsey SC, Kwon O, Xu GW, Burant CF, Simpson I, Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997;272(30):18982-9. (Pubitemid 27318253)
16. Rumsey SC, Daruwala R, Al-Hasani H, Zarnowski MJ, Simpson IA, Levine M. Dehydroascorbic acid transport by GLUT4 in Xenopus oocytes and isolated rat adipocytes. J Biol Chem. 2000;275(36):28246-53.
17. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93(1):268-77. (Pubitemid 29019412)
18. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem. 2005;280(51):41928-39. (Pubitemid 43023162)
19. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol. 2007;27(3):912-25. (Pubitemid 46174556)
20. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003;63(8):1764-8. (Pubitemid 36460834)
21. Vissers MC, Gunningham SP, Morrison MJ, Dachs GU, Currie MJ. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med. 2007;42(6):765-72. (Pubitemid 46274164)
22. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res. 2006;66(5):2600-7.
23. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005;102(38):13604-9. (Pubitemid 41420895)
24. Rosenblat G, Graham MF, Jonas A, Tarshis M, Schubert SY, Tabak M, et al. Effect of ascorbic acid and its hydrophobic derivative palmitoyl ascorbate on the redox state of primary human fibroblasts. J Med Food. 2001;4(2):107-15. (Pubitemid 32738510)
25. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54(13):3352-6. (Pubitemid 24225946)
26. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533-7.
27. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA. 1996;93(8):3704-9. (Pubitemid 26125678)
28. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60. (Pubitemid 40282557)
29. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363-80. (Pubitemid 30660013)
30. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-84. (Pubitemid 30122932)
31. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007;104(39):15549-54. (Pubitemid 47502954)
32. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732-40. (Pubitemid 44085631)
33. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996;103(2):183-9. (Pubitemid 26147697)
34. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002;8(12):3658-68. (Pubitemid 35424755)